CMMB
Chemomab Therapeutics Ltd.
Healthcare — Biotechnology
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
None
2 analysts
$1.30
+$0.11 (+9.24%)
Target:
$15.00
(1053.8%)
Price History
52-Week Range
Sign in to add CMMB to a watchlist or set price alerts.
Fundamentals
| Market Cap | $12.24M |
| P/E Ratio (TTM) | - |
| Forward P/E | -56.67 |
| EPS (TTM) | $-1.12 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -70.61% |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | $15.00 |
| Analysts | 2 |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 46.2 |
| Beta | 0.61 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $4.92 |
| 52-Week Low | $1.35 |
| 50-Day Avg | $1.69 |
| 200-Day Avg | $2.06 |
| Avg Volume | 43.5K |
| Volume | 62.1K |
Performance Analysis
NEUTRALCMMB presents a mixed picture with both positive and negative indicators.
+
Trading near its 52-week low ($1.35), which could present a value opportunity.
~
RSI at 46.2 is in neutral territory.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
~
Wall Street consensus is "none" from 2 analysts.
+
Average analyst target of $15.00 implies 1053.8% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:03 UTC
Back to Screener Export Report